Burstable Health Team
Health In-Focus
@burstable
Burstable News™ is a hosted solution designed to help businesses build an audience and enhance their AIO and SEO press release strategies by automatically providing fresh, unique, and brand-aligned business news content. It eliminates the overhead of engineering, maintenance, and content creation, offering an easy, no-developer-needed implementation that works on any website. The service focuses on boosting site authority with vertically-aligned stories that are guaranteed unique and compliant with Google's E-E-A-T guidelines to keep your site dynamic and engaging.
3348 articles
Articles
AI Chatbots Fail to Reliably Identify Validated Home Blood Pressure Monitors, Study Finds
A new study presented at the American Heart Association's Hypertension Scientific Sessions 2026 reveals that popular AI search tools often misidentify validated home blood pressure monitors, potentially leading to inaccurate readings and inappropriate treatment decisions.
October 8, 2026Read the full article
Avident Health and Unite for HER Receive NCCN and Pfizer Grant to Improve Metastatic Breast Cancer Care
Avident Health and Unite for HER have been awarded a quality improvement grant from Pfizer and NCCN to deploy a digital navigation platform that enhances education, supportive care access, and caregiver engagement for metastatic breast cancer patients.
October 8, 2026Read the full article
Avatar Medical Vision Earns CE Mark for Glasses-Free 3D Surgical Planning
Avatar Medical has received CE Marking for Avatar Medical Vision, making it the first software approved for use with a glasses-free 3D medical display, which could streamline surgical planning and patient consultations across Europe.
October 8, 2026Read the full article
Avatar Medical Secures CE Marking for Glasses-Free 3D Medical Imaging Software
Avatar Medical has obtained CE marking for its Avatar Medical Vision software, the first such approval for a platform compatible with glasses-free 3D medical displays, enabling commercialization in Europe and advancing surgical planning and consultation.
October 8, 2026Read the full article
New Guidance Urges Breast Cancer Risk Assessment by Age 25, Not 40
The American College of Radiology now recommends that all women undergo a formal breast cancer risk assessment by age 25 to enable personalized screening and earlier detection, especially for high-risk groups.
October 8, 2026Read the full article
Quantum BioPharma Partners with Thermo Fisher to Launch Phase 2 Lucid-MS Trial for Multiple Sclerosis
Quantum BioPharma has signed a Study Start-Up Agreement with Thermo Fisher Scientific's clinical research business to initiate a Phase 2 trial of Lucid-MS, a novel neuroprotective treatment for multiple sclerosis.
October 7, 2026Read the full article
VERAXA Biotech Advances FDA-Aligned Methods to Reduce Animal Testing in Cancer Research
VERAXA Biotech's new FDA-aligned approach could cut animal testing and speed up development of cancer therapies.
October 7, 2026Read the full article
SS Innovations Advances Telerobotic Surgery with 195 Remote Procedures
SS Innovations International reports 195 telesurgeries and a 45% increase in its SSi Mantra installed base, highlighting the growing momentum of remote robotic surgery as the company pursues FDA clearance and CE marking.
October 7, 2026Read the full article
Lantern Pharma Gains Taiwan Approvals for Phase 2 HARMONIC Trial of LP-300 in Lung Cancer
Lantern Pharma has received regulatory and IRB approvals in Taiwan to open Part 2 of its Phase 2 HARMONIC trial of LP-300, potentially accelerating development of a targeted therapy for EGFR L858R mutated non-small cell lung cancer.
October 7, 2026Read the full article
Quantum BioPharma Partners with Thermo Fisher to Launch Phase 2 Trial of Lucid-MS, a Novel Neuroprotective Approach to Multiple Sclerosis
Quantum BioPharma has signed a Study Start-Up Agreement with Thermo Fisher Scientific's clinical research business to implement a Phase 2 trial of Lucid-MS, a drug candidate that targets demyelination rather than solely modulating the immune system, potentially offering a new treatment paradigm for multiple sclerosis.
October 7, 2026Read the full article
XORTX Therapeutics Advances XORLO for Gout with FDA Submission on the Horizon
XORTX Therapeutics is developing XORLO, a new gout treatment that may offer better tolerability than existing therapies, as it prepares for an FDA new drug application submission.
October 7, 2026Read the full article
National C60 Day Highlights Growing Interest in Fullerene Wellness Research
C60 Power marks National C60 Day on October 9 with a 20% sale and educational events, drawing attention to fullerenes' potential in health and longevity.
October 7, 2026Read the full article
National C60 Day Highlights Nobel Prize-Winning Molecule and Its Potential in Healthy Aging Research
C60 Power celebrates National C60 Day on October 9 to honor the discovery of Carbon 60 and promote education on its potential health benefits, offering a 20% storewide sale and research resources.
October 7, 2026Read the full article
Telomir Pharmaceuticals Raises $5.6M PIPE to Advance Telomir-Zn into Phase 1/2 TNBC Trial
Telomir Pharmaceuticals has secured approximately $5.6 million in PIPE financing to support clinical development of Telomir-Zn, its lead candidate for advanced or metastatic triple-negative breast cancer.
October 6, 2026Read the full article
Quantum BioPharma Initiates Phase 2 Trial of Lucid-MS for Multiple Sclerosis with Thermo Fisher Support
Quantum BioPharma has signed a Study Start-Up Agreement with Thermo Fisher Scientific to launch a Phase 2 trial of Lucid-MS, a first-in-class neuroprotective candidate for progressive multiple sclerosis, following FDA clearance.
October 6, 2026Read the full article
Skull's Hidden Lymphatic Structures May Revolutionize Brain Disease Treatment
A new study reveals lymph-node-like structures in the skull's bone marrow, suggesting the brain has a localized immune defense system that could lead to innovative treatments for brain cancers and other neurological diseases.
October 6, 2026Read the full article
Kairos Pharma's ENV-105 Shows Significant Progression-Free Survival Benefit in Phase 2 Prostate Cancer Trial
Kairos Pharma's ENV-105 combined with apalutamide significantly improved progression-free survival in metastatic castration-resistant prostate cancer, leading to a protocol amendment to enroll patients earlier in disease progression.
October 6, 2026Read the full article
AXIM Biotechnologies Submits 510(k) to FDA for Rapid Point-of-Care Tear Lactoferrin Test for Dry Eye Disease
AXIM Biotechnologies has submitted a 510(k) to the FDA for a next-generation, rapid point-of-care test that measures tear lactoferrin to aid in diagnosing aqueous deficient dry eye disease, with plans to seek CLIA waiver to expand access.
October 6, 2026Read the full article
BFCH and NEXT10 Outline Plan to Build Scalable Health, Wellness and Longevity Platform
BitFrontier Capital Holdings and NEXT10 have detailed a strategy to build UNLOCKD into a scalable health, wellness, and longevity platform, targeting 5-7 consumer brands, $65-$95 million in annual revenue, and approximately 62 wellness centers over three to five years.
October 6, 2026Read the full article
Market Street Capital Bridges Capital Markets Discipline and Healthcare Financing Amid Reimbursement Shifts
Market Street Capital is applying capital markets discipline to middle-market healthcare financing as reimbursement delays and consolidation pressure reshape how clinical labs and diagnostics operators structure capital raises.
October 5, 2026Read the full article
NHS Rapid Brain Tumor Test Cuts Diagnosis Wait to Two Hours, Boosting Biotech Treatment Prospects
A new rapid brain tumor test developed by the University of Nottingham and adopted by NHS England reduces diagnosis time from eight weeks to about two hours, potentially accelerating access to treatments from biotech companies like CNS Pharmaceuticals.
October 5, 2026Read the full article